Novus Therapeutics, Inc. (NVUS) Gets a Buy Rating from Ladenburg Thalmann & Co.

By Austin Angelo

In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Novus Therapeutics, Inc. (NVUSResearch Report), with a price target of $10. The company’s shares closed last Monday at $0.79, close to its 52-week low of $0.71.

According to TipRanks.com, Higgins has 0 stars on 0-5 star ranking scale with an average return of -12.5% and a 28.3% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Armata Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Achieve Life Sciences Inc.

Currently, the analyst consensus on Novus Therapeutics, Inc. is a Moderate Buy with an average price target of $10.

See today’s analyst top recommended stocks >>

Based on Novus Therapeutics, Inc.’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $4.09 million. In comparison, last year the company had a GAAP net loss of $3.19 million.

Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Novus Therapeutics Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of products for disorders of the ear, nose, and throat. Its product pipelines include OPO201; OP0101; and OP0102. The company was founded on March 26, 2004 and is headquartered in Irvine, CA.